We are live on ! Find out more
BLRX

BioLineRX

31 hedge funds and large institutions have $2.42M invested in BioLineRX in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

63% more capital invested

Capital invested by funds: $1.49M → $2.42M (+$935K)

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

7% more funds holding

Funds holding: 2931 (+2)

0.01% more ownership

Funds ownership: 0%0.01% (+0.01%)

49% less call options, than puts

Call options by funds: $35K | Put options by funds: $69K

Holders
31
Holders Change
+2
Holders Change %
+6.9%
% of All Funds
0.45%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
9
Reduced
6
Closed
4
Calls
$35K
Puts
$69K
Net Calls
-$34K
Net Calls Change
+$156K
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$850 +$1.02K +38 New
UBS Group
27
UBS Group
Switzerland
$844 -$7.44K -277 -88%
Osaic Holdings
28
Osaic Holdings
Arizona
$801 +$134 +5 +17%
GI
29
GAMMA Investing
California
$124 -$2.55K -95 -95%
TCM
30
Tradewinds Capital Management
Washington
$114
XT
31
XTX Topco
Cayman Islands
-$35.3K -787 Closed
BRWA
32
B. Riley Wealth Advisors
Florida
-$38.8K -533 Closed
Group One Trading
33
Group One Trading
Illinois
-$2.15K -80 Closed
Simplex Trading
34
Simplex Trading
Illinois
-$1.34K -50 Closed

BLRX Hedge Fund Activity: Q2 2024 in Review

31 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2024, worth a combined $2.42M — up 63% from $1.49M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BLRX positions and 4 closed out — a net gain of 3 holders — while 9 added to existing stakes and 6 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $1.31M. The largest seller was Morgan Stanley, cutting an estimated $150K.

  • 31 institutional investors held BioLineRX (BLRX) as of Q2 2024, up from 29 in Q1 2024.
  • Funds reported $2.42M of BioLineRX stock for Q2 2024, up 63% quarter-over-quarter.
  • 7 funds opened new BioLineRX positions in Q2 2024 and 4 closed out, a net change of +3 holders.
  • The largest BioLineRX buyer in Q2 2024 was Alyeska Investment Group, an estimated $1.31M added.
  • The largest BioLineRX seller in Q2 2024 was Morgan Stanley, an estimated $150K sold.

Based on aggregated 13F filings for Q2 2024.